Highest-materiality recent filing
Board size increased from one to four directors effective April 1, 2026.
Global Innovative Platforms posts updated investor presentation on website
Presentation posted March 31, 2026, available at www.vetbreath.com under Investor Relations.
Preliminary analysis of breath samples using VOCAM Plus identified a consistent VOC profile distinguishing heartworm-infected from uninfected dogs.
Inks diagnostic supply deal with animal health co; switches auditor to CNGSN
Agreement to supply VOCAM Plus units and support for evaluation of canine heartworm detection using breathomics.
Global Innovative Platforms posts updated investor presentation on its website
Company filed Form 8-K on September 26, 2025 for Regulation FD disclosure.
Global Innovative Platforms posts updated investor presentation; no material new details disclosed
Updated investor presentation made available on company website on June 23, 2025.
On April 1, 2026, the Board of Directors (the “Board”) of Global Innovative Platforms Inc. (the “Company”) appointed the following individuals to serve as directors of the Company, effective immediately:
On April 1, 2026, the Board of Directors (the “Board”) of Global Innovative Platforms Inc. (the “Company”) appointed the following individuals to serve as directors of the Company, effective immediately:
On April 1, 2026, the Board of Directors (the “Board”) of Global Innovative Platforms Inc. (the “Company”) appointed the following individuals to serve as directors of the Company, effective immediately:
On April 1, 2026, the Board of Directors (the “Board”) of Global Innovative Platforms Inc. (the “Company”) appointed the following individuals to serve as directors of the Company, effective immediately:
Max materiality 0.65 · Median 0.35 · Most common event other_material